Investigating the Investigators: Another Headache for Drug Sponsors
This article was originally published in RPM Report
Executive Summary
One leading indicator of a more enforcement-minded approach at the Food & Drug Administration may be a crackdown on clinical trial investigators suspected of fraud. One thing is already clear: sponsors who rely on investigators who trigger suspicions will pay a price in the form of an even tougher time getting the drug through FDA.